Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pluristem Therapeutics Inc. PSTI
$1.00
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
40848400.00000000
-
week52high
-
week52low
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.91272800
-
EPS
-1.46200000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 сент 2022 г. в 04:00
Описание компании
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Alliance Global Partners | Buy | Buy | 20 июл 2022 г. |
| Alliance Global Partners | Buy | 04 мая 2021 г. | |
| Jefferies | Hold | Buy | 10 дек 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 10 дек 2020 г. |
| Jefferies | Buy | Buy | 25 ноя 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Aberman Zami | A | 91756 | 80616 | 10 февр 2022 г. |
| Birger Pinhas Doron | A | 20000 | 20000 | 15 июл 2021 г. |
| Shalev Varda | A | 20000 | 20000 | 15 июл 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3121918 | 45000 | 28 мая 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3166918 | 70007 | 28 мая 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3236925 | 24110 | 27 мая 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3261035 | 71775 | 27 мая 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3332810 | 22015 | 26 мая 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3354825 | 122663 | 26 мая 2021 г. |
| CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | D | 3477488 | 261238 | 25 мая 2021 г. |
Новостная лента
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Zacks Investment Research
14 июл 2022 г. в 12:24
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
Benzinga
13 июл 2022 г. в 09:59
Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short.